Wikipedia -WSS

Wikipedia

author：explore 2025-09-29 23:27:51 - browse：985

An ALS patient receives support. -- health coverage from STAT — Adobe

Years of polarizing scientific discourse and bruising online debate will come to a head next week when advisers to the Food and Drug Administration weigh in on NurOwn, a potential treatment to slow the progression of ALS that has bitterly divided physicians and patient advocates.

On Sept. 27, a panel of experts will consider the convoluted data supporting the potential approval of NurOwn, a stem-cell therapy the FDA previously refused to even consider. To some physicians, the drug’s failure to show significant benefits in clinical studies leaves approval out of the question. Others, including the influential ALS Association, say NurOwn’s manufacturer, a small biotech firm called BrainStorm Cell Therapeutics, hasn’t disclosed enough information to properly determine the medicine’s value.

Another group of patients and doctors argue that NurOwn’s supporting evidence, while problematic, justifies making it available to the roughly 30,000 ALS patients in the U.S., people for whom there is currently no hope of arresting an incurable disease that gradually erodes motor function and leads to death within about five years of diagnosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Just how powerful is the placebo effect?

focus

WSS

Readout LOUD podcast, live from the STAT Breakthrough Summit East

Ibogaine psychedelic therapy for opioid addiction unlikely, official says

Will General Catalyst be the first of many hospital takeovers?

Free speech concerns arise in wake of journal editor Eisen's firing

Victims of gun violence feel impacts long after bullet wound

'Patient friction coefficient' can gauge a clinical trial's patient burden

hotspot

Wikipedia

hotspot

Tori Bowie and the unacceptable rates of Black maternal death

Medicare solvency divides Republicans at the presidential debate

Hollywood unions extend contract negotiations for actors

AstraZeneca CEO says participant had neurological symptoms, could be discharged today

Dobbs anniversary: the lost opportunity of abortion as health care

FDA approves Recor Medical high blood pressure device

Moonlake's readout produced a cash windfall. Risks remain

U.K. officials, researchers try to ease path for bespoke genetic treatments

In age of alternative facts, a scholarly course on calling out crap

The new shift in health care is toward less care

focus

AstraZeneca CEO says participant had neurological symptoms, could be discharged today

Asbestos ban is immediate, but health effects will linger for decades

Ambulance rides for just $100? Advisers want major billing fixes

Victims of gun violence feel impacts long after bullet wound

Senate panel clears PBM, hopsital reforms

A clever new way to fix Medicaid and graduate medical education

focus

hotspot

focus

focus